The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: A systematic review and meta-analysis

Clinical Rheumatology

Volumn 32, Issue 10, 2013, Pages 1415-1424

  Kawalec, Paweł ^a,b   Mikrut, Alicja ^b   Winiewska, Natalia ^b   Pilc, Andrzej ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b Centrum HTA w Krakowie   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Meta analysis; Rheumatoid arthritis; Systematic review; Tofacitinib

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; TOFACITINIB;

COCHRANE LIBRARY; DATA BASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HEALTH STATUS; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; MEDLINE; META ANALYSIS; MONOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885311733     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-013-2329-9     Document Type: Review

References (28)

1. Tanaka Y, Yamaoka K (2013) JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 23:415-424
2. Zerbini CA, Lomonte AB (2012) Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 8:319-331
3. Bannwarth B, Kostine M, Poursac N (2013) A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol 9:753-761
4. Singh JA, Furst DE, Bharat A, et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625-639
5. Riese RJ, Krishnaswami S, Kremer J (2010) Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 24:513-526
6. Food and Drug Administration (2012) Advisory Committee meeting. Tofacitinib for treatment of rheumatoid arthritis (NDA 203214). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf. Accessed 3 May 2013
7. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Cochrane Collaboration, Oxford. www.cochrane-handbook.org. Accessed 3 May 2013
8. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 151:264-9
9. Jadad AR, Moore RA, Carroll D, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12
10. Felson DT, Anderson JJ, Boers M, et al. (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727-735
11. Tanaka Y, Suzuki M, Nakamura H, et al. (2011) Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 63:1150-58. http://www.clinicaltrials.gov/ct2/show/results/ NCT00603512. Accessed 3 May 2013
12. Kremer JM, Cohen S, Wilkinson BE, et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64:970-81. http://clinicaltrials.gov/ct2/show/results/NCT00413660?sect=X9876015. Accessed 3 May 2013
13. van Vollenhoven RF, Fleischmann R, Cohen S, et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508-19. http://clinicaltrials.gov/ct2/show/results/NCT00853385. Accessed 3 May 2013
14. Burmester GR, Blanco R, Charles-Schoeman C, et al. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451-60. http://clinicaltrials.gov/ct2/show/ NCT00960440. Accessed 3 May 2013
15. van der Heijde D, Tanaka Y, Fleischmann R, et al. (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559-70. http://clinicaltrials.gov/ct2/show/results/ NCT00847613. Accessed 3 May 2013
16. Fleischmann R, Kremer J, Cush J, et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495-507. http://clinicaltrials.gov/ct2/show/results/NCT00814307. Accessed 3 May 2013
17. Fleischmann R, Cutolo M, Genovese MC, et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617-29. http://clinicaltrials.gov/ct2/show/results/ NCT00550446. Accessed 3 May 2013
18. Kremer JM, Bloom BJ, Breedveld FC, et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60:1895-1905
19. Coombs JH, Bloom BJ, Breedveld FC, et al. (2010) Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 69:413-416
20. Tanaka Y, Takeuchi T, Yamanaka H, et al. (2011) Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week phase 2b study [abstract]. Arthritis Rheum 63 Suppl 10:2192
21. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
22. Cohen S, Zwillich S, Chow V, et al. (2010) Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 69:143-151
23. Wiens A, Correr CJ, Venson R, et al. (2009) A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28:1365-1373
24. Aaltonen KJ, Virkki LM, Malmivaara A, et al. (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 7:e30275
25. Orme ME, MacGilchrist KS, Mitchell S, et al. (2012) Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 6:429-464
26. Yang CT, Kuo CF, Luo SF, Yu KH (2012) Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis. Clin Rheumatol 31:1549-1557
27. Salgado E, Maneiro JR, Carmona L, Gomez-Reino JJ (2013) Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-203116
28. American College of Rheumatology Committee to Reevaluate Improvement Criteria (2007) A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum 57:193-202